Retatrutide is a weekly injection, while semaglutide is available as both a weekly injection or a daily pill
In the liver, it decreases glucose production, while in the pancreas it promotes insulin release and beta-cell proliferation
Smaller, more frequent meals maintain more consistent blood sugar levels and prevent the extreme hunger that can follow a long gap between meals
Common injection site reactions include pain and bleeding, which typically resolve within a few days
Please see updated joint guidance from PCDS and ABCD, available here
The FDA peptide regulations 2026 refer to the reclassification of several popular peptides, including BPC-157, TB-500, KPV, MOTs-c, and GHK-Cu, into Category 2 bulk drug substances